PLAINSBORO, N.J., Jan. 4, 2021 /PRNewswire/ -- Today, Novo
Nordisk announced the extension of its COVID-19 Patient Assistance
Program until June 30, 2021, for
those who have lost health insurance coverage because of a change
in job status due to the pandemic.
The company also would like to remind people who are currently
using the My$99Insulin program that they must reregister to
determine if they are eligible for the cash card program.
For people looking to find out what option makes the most sense
for their particular situation, information and eligibility
criteria about these and other offerings are available online at
NovoCare.com or by calling 1.844.NOVO4ME (1.844.668.6463).
"Last January, we created new programs to meet the varying needs
of patients whether they have insurance or don't and made them
available on Novocare.com. Then, the pandemic hit and patients
faced new challenges - millions of people lost their jobs and very
likely their health coverage so we knew we needed to do more
specific to the pandemic," said Doug Langa, Executive Vice
President, North America Operations and President of Novo
Nordisk Inc. "The need is still present - our nation is not back to
normal and our economic and public health reality is still
challenging. So, we're continuing our COVID -19 assistance program
and encouraging anyone facing affordability challenges to visit our
one-stop support resource to find the option most suitable to
them."
Important updates in Novo Nordisk's affordability
programs
- COVID-19 Patient Assistance Program: Launched in
April 2020, people with diabetes
using Novo Nordisk insulin who lost health insurance coverage
because of a change in job status due to the COVID-19 pandemic
could enroll in our Diabetes Patient Assistance Program (PAP) and
receive insulin free of charge for 90 days. The program has been
extended until June 30, 2021.
Eligibility criteria can be found on NovoCare.com or by calling
1.844.NOVO4ME (668.6463)
- My$99Insulin: My$99Insulin enables eligible patients to
purchase up to three vials or two packs of
FlexPen®/FlexTouch®/PenFill® pens
of any combination of insulins for $99. Patients who enrolled in the My$99 Insulin
program in 2020 should review the details of the program on
NovoCare.com to determine if they are eligible to re-register in
2021
Novo Nordisk offers a number of other affordability programs,
including:
- Our long-standing Patient Assistance Program (PAP),
which has provided free medicines to eligible patients since 2003,
has been enhanced to reflect today's public health crisis.
Historically, more than 50,000 patients have received free insulin
each year through this program. Effective April 1, 2020, Medicare patients who qualify for
PAP are no longer required to pay $1,000 for medicines before being eligible for
the Novo Nordisk PAP
- Unbranded biologic insulins: Unbranded biologics of
NovoLog® and NovoLog® Mix, from Novo Nordisk
Pharma, Inc. (NNPI), a Novo Nordisk A/S US company, can be ordered
at one's local pharmacy and cost 50 percent off the current list
prices of the branded medicines
- Immediate Supply: We also know that there may be
instances when people are struggling and need insulin immediately
because they might be at risk of rationing. People in this
situation can call us at 1.844.NOVO4ME (1.844.668.6463) or visit
NovoCare.com to see if we can provide a free, one-time, immediate
supply of up to three vials or two packs of pens of Novo Nordisk
insulin for individuals with a prescription
- Novo Nordisk human insulin is available at national
pharmacies like Walmart and CVS for about $25/vial. About 500,000 Americans are using Novo
Nordisk human insulin through these retailers
- Copay Savings Cards can help defray the costs for
commercially insured patients who are experiencing high
out-of-pocket costs
To learn more about these offerings and view full eligibility
requirements, please visit NovoCare.com.
Additionally, we'll continue working towards longer-term reform
that makes it easier for people who need our medicines to get them.
For instance, we advocate that payers adopt a 2019 IRS rule
classifying insulin as preventive care, which could help a
significant number of people overcome affordability
barriers.
About NovoCare.com
NovoCare.com is Novo Nordisk's
go-to resource for all US patient affordability and access support
programs. Available 24 hours a day, NovoCare.com provides all
necessary information, including eligibility details, affordability
options, assistance programs for those in need of insulin. Help is
also available at 1.844.NOVO4ME (668.6463).
About Novo Nordisk Inc. (NNI)
NNI is a US affiliate of
Novo Nordisk. The company is based in Plainsboro, NJ and
is responsible for commercialization of Novo Nordisk brands in the
US and management of clinical trials in the US. For more
information,
visit novonordisk.us, Facebook, Instagram and Twitter.
About Novo Nordisk Pharma, Inc. (NNPI)
Novo
Nordisk Pharma, Inc. (NNPI) is a newly established Novo Nordisk A/S
US company that is also based in Plainsboro, NJ. The company
was formed in March 2019 to bring unbranded biologics of
Novo Nordisk insulin products at a reduced list price for people
facing affordability challenges.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/novo-nordisk-extends-covid-19-patient-assistance-program-encourages-people-facing-affordability-challenges-to-visit-novocarecom-301200105.html
SOURCE Novo Nordisk